Company continues progress across Ampligen® clinical development programs
Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications
Recent Highlights
- AMP-518 Clinical Study: Phase 2 study evaluating Ampligen as a potential therapeutic for people with the Post-COVID condition of fatigue
- Completed treatment in study
- Reported positive topline results offering preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions
- Bolstered intellectual property estate with issuance of key
U.S. patent for Ampligen in combination with an anti-PD-L1 antibody for the treatment of cancer - DURIPANC Clinical Study: Phase 1b/2 clinical trial combining AIM’s Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of pancreatic cancer
- Opened for enrollment and enrolled first subject at
Erasmus Medical Center (“Erasmus MC”) - First subject dosed at Erasmus MC
- Opened for enrollment and enrolled first subject at
“AIM’s emphasis throughout 2024 will be building upon our strong foundation of scientific success,” said AIM Chief Executive Officer
Upcoming Expected Ampligen Milestones
Q1 2024
- Advanced Recurrent Ovarian Cancer – Protocol-planned interim results
Q2 2024
- Post-COVID Conditions (AMP-518) – Final dataset
2024
- Locally Advanced Pancreatic Adenocarcinoma (AMP-270) – First subject dosed
- Publications of data in scientific journals
Ongoing Business Development Update
As previously announced, the Company engaged
In addition to its ongoing clinical and business development activities, the Company will continue to engage with the industry and investment communities by actively participating in meetings, virtual events and key conferences over the course of the year. To stay up to date with the Company’s activities visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
About
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the
Investor Contact:JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
Source:
2024 GlobeNewswire, Inc., source